Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat ...

The effects of MMP-2 inhibition on arsenic-induced mesenchymal changes of lung epithelial cells were examined. By using a selective inhibitor for MMP-2, ARP-100, the arsenic-induced fibronectin and ...

Specifically, platelet activation and blood clotting capacity are increased; in addition, fibronectin, the protein that connects lung tissue cells, is activated. It is an established fact that ...

Harmful infectious organisms are identified as invaders due to their antigens (distinct molecules on their surface). Each antibody produced by your immune system binds to a specific antigen and then ...

WFS1 and CISD2 regulate IP3R activity through their interaction. In Wolfram syndrome, their dysfunction reduces cytosolic ...

As of December 31, 2024, Pyxis Oncology had cash and cash equivalents, including restricted cash, and short-term investments, of $128.4 million. The Company believes that its current cash, cash ...

Neutrophils help strengthen and maintain the skin’s structure by depositing proteins like collagen and fibronectin. Previously, this role was thought to be solely the responsibility of fibroblasts, ...

The lead product candidate, micvotabart pelidotin ("MICVO” formerly PYX-201), is an antibody-drug conjugate (ADC) that uniquely targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural ...

Expression data from patient-derived xenograft (PDX) mouse models exposed to micvotabart pelidotin (MICVO) indicate gene signatures associated with efficacy, deepening understanding of MOA and ...

PYX-201 is a first-in-concept antibody-drug conjugate and works by targeting extra domain-B fibronectin, which is a non-cellular structural component highly expressed in several tumor types. Two ...